Compare Estee Lauder Companies Inc (EL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Sana Biotechnology Inc — how do they compare? Estee Lauder Companies Inc trades at $88 (market cap $31.76B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Estee Lauder Companies Inc is far larger — about 28.1× Sana Biotechnology Inc's market cap, and Estee Lauder Companies Inc pays a 1.59% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| EL | SANA | |
|---|---|---|
Market Cap | $31.76B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $5.92 |
52-Week Low | $67.23 | $2.68 |
Enterprise Value | $37.93B | $1.05B |
Dividend Yield | 1.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EL trades at $87.70, up 0.58% on the day, with a bullish technical signal from moving averages and a consensus price target of $91.67. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.13 billion for 2025. Revenue has declined from $17.7 billion in 2022 to $14.33 billion in 2025, but positive cash flow from operations of $1.27 billion provides liquidity. A new fragrance launch and executive appointment signal ongoing brand development efforts.
The stock presents a mixed outlook. Analyst sentiment is divided with a slight Hold bias, yet technical momentum and earnings beats offer near-term upside potential. Key risks include sustained negative net income margins, high debt levels, and competitive pressures in the beauty sector. The upcoming Q2 2026 earnings report on August 19, 2026, will be critical for validating the recent positive earnings trend and guiding future price direction.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
